Navamedic ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Navamedic ASA announces FY 2014 financial guidance
Navamedic ASA:Expects continued sales growth in H2 2014, both organically and through the addition of new products.
Latest Key Developments in Pharmaceuticals
- Supreme Pharmaceuticals Inc appoints new President
- AstraZeneca Plc's LYNPARZA approved by the US FDA
- Roche Holding AG acquires Bina Technologies and enters genomic informatics market
- Teva Pharmaceutical Industries Ltd announces FDA approval of QNASL Nasal Aerosol for treatment of children with seasonal and Perennial Allergic Rhinitis
- Share this
- Digg this